Another preclinical study demonstrated that targeting MALAT1 with modified ASOs promotes the differentiation of tumor cells and decreases tumor growth in a breast cancer mouse model (Arun et al., 2016)—a strategy that may be suitable for other solid cancers, including glioblastoma. This evidence concerns the gene MALAT1 and neoplasm.